Zhejiang Huakang Pharmaceutical Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Zhejiang Huakang Pharmaceutical Co., Ltd. carries a market capitalization of 3.32B, placing it among publicly traded companies globally. Its enterprise value stands at 7.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.32B |
| Enterprise Value | 7.00B |
Share Statistics
Zhejiang Huakang Pharmaceutical Co., Ltd. currently has 303.05M shares outstanding.
| Shares Outstanding | 303.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zhejiang Huakang Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 18.41. The price-to-sales ratio is 1.46, and the price-to-book ratio stands at 3.27.
| PE Ratio | 18.41 |
| PS Ratio | 1.46 |
| PB Ratio | 3.27 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | 7.06 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zhejiang Huakang Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 21.06 and an EV/FCF ratio of 7.79. The EV/Sales ratio of 2.11 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.06 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.11 |
| EV / EBITDA | 21.06 |
| EV / EBIT | 21.06 |
| EV / FCF | 7.79 |
Financial Position
Zhejiang Huakang Pharmaceutical Co., Ltd. maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.29, indicating elevated leverage, while an interest coverage ratio of 5.55 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.65 |
| Quick Ratio | 0.44 |
| Debt / Equity | 91.29 |
| Debt / EBITDA | 8.91 |
| Interest Coverage | 5.55 |
Financial Efficiency
Zhejiang Huakang Pharmaceutical Co., Ltd. posts a return on equity of 18.45 and a return on invested capital of 5.33.
| Return on Equity (ROE) | 18.45 |
| Return on Assets (ROA) | 3.90 |
| Return on Invested Capital (ROIC) | 5.33 |
| Return on Capital Employed (ROCE) | 7.99 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.63 |
Taxes
Over the trailing twelve months, Zhejiang Huakang Pharmaceutical Co., Ltd. has paid 25.48M in income taxes, reflecting an effective tax rate of 8.76.
| Income Tax | 25.48M |
| Effective Tax Rate | 8.76 |
Stock Price Statistics
Zhejiang Huakang Pharmaceutical Co., Ltd.'s stock has declined approximately -32.42259% over the past 52 weeks. The 50-day moving average sits at 15.33, while the 200-day moving average is 15.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.42259% |
| 50-Day Moving Average | 15.33 |
| 200-Day Moving Average | 15.98 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang Huakang Pharmaceutical Co., Ltd. generated 3.32B in revenue and converted that into 263.81M in net income, yielding earnings per share of 0.72. EBITDA reached 332.32M, while operating income came in at 332.32M.
| Revenue | 3.32B |
| Gross Profit | 649.55M |
| Operating Income | 332.32M |
| Pretax Income | 290.79M |
| Net Income | 263.81M |
| EBITDA | 332.32M |
| EBIT | 332.32M |
| Earnings Per Share (EPS) | 0.72 |
Balance Sheet
Zhejiang Huakang Pharmaceutical Co., Ltd. holds 830.56M in cash and equivalents against 2.96B in total debt, resulting in a net debt position of 1.96B. Total book value stands at 1.49B, with working capital of 1.21B providing operational flexibility.
| Cash & Cash Equivalents | 830.56M |
| Total Debt | 2.96B |
| Net Debt | 1.96B |
| Equity (Book Value) | 1.49B |
| Book Value Per Share | 4.95 |
| Working Capital | 1.21B |
Cash Flow
After subtracting -844.06M in capital expenditures, free cash flow totaled -844.06M - equivalent to -2.81 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -844.06M |
| Free Cash Flow | -844.06M |
| FCF Per Share | -2.81 |
Margins
Zhejiang Huakang Pharmaceutical Co., Ltd. operates with a gross margin of 19.59, reflecting its pricing power and cost economics. The operating margin of 10.02 and net profit margin of 7.96 provide insight into operational efficiency.
| Gross Margin | 19.59 |
| Operating Margin | 10.02 |
| Pretax Margin | 8.77 |
| Profit Margin | 7.96 |
| EBITDA Margin | 10.02 |
Dividends & Yields
The company's payout ratio of 69.33 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.62 |
| Dividend Yield | N/A |
| Payout Ratio | 69.33 |
| Shareholder Yield | -8.18 |
| FCF Yield | 14.16 |
Stock Splits
Zhejiang Huakang Pharmaceutical Co., Ltd.'s most recent stock split took place on May 28, 2024 with a 10:13 split ratio.
| Last Split Date | 5/28/2024 |
| Split Ratio | 10:13 |
Scores
Zhejiang Huakang Pharmaceutical Co., Ltd. posts an Altman Z-Score of 1.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.76 |